drugset / Trial / NCT05308940
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of TB001 in Healthy Subjects
RandomizedParallel-groupQuadruple-blindOther
Summary
It was a randomized, double-blind, placebo-controlled combined single ascending dose (SAD) and multiple ascending dose (MAD) study, evaluating the safety, tolerability and pharmacokinetics of TB001 after single and multiple subcutaneous injections in healthy subjects.
Timeline
- Start
- 2022-01-10
- Primary completion
- 2022-08-23
- Completion
- 2022-08-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TB001 | Unknown | 20 ug | Subcutaneous |
| Subject | TB001 | Unknown | 60 ug | Subcutaneous |
| Subject | TB001 | Unknown | 150 ug | Subcutaneous |
| Subject | TB001 | Unknown | 300 ug | Subcutaneous |
| Subject | TB001 | Unknown | 600 ug | Subcutaneous |
| Subject | TB001 | Unknown | 900 ug | Subcutaneous |
Indications
No indication recorded.